Company intelligence / Profile preview
Azome Therapeutics
Malvern, Pennsylvania, United Statesazometherapeutics.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Azome's lead drug candidate AZM-152 has shown promising results in preclinical studies across seven different models of lung inflammation. The company has entered into a CRADA with the National Center for Advancing Translational Sciences to investigate AZM-152 for preventing Bronchopulmonary Dysplasia.
- Therapeutic areas
- PulmonologyNephrologyInfectious Diseases
- Modalities
- Peptides (AZM-152)Small molecules (in development)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Center for Advancing Translational Sciences (NCATS)
Beyond the preview
Go deeper on Azome Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Azome Therapeutics.